

AMENDMENTS TO THE CLAIMS

1.-22. **(Cancelled)**

23. **(New)** An isolated neuropilin binder (NPB), wherein the NPB is an antibody, antibody fragment or bioconjugate that specifically binds to neuropilin-1 without inhibiting the VEGF/neuropilin-1 interaction.

24. **(New)** The NPB of claim 23, comprising the sequence set forth in SEQ ID No.: 15.

25. **(New)** The NPB of claim 23, comprising a VH domain comprising amino acid residues 1 to 116 of the sequence set forth in SEQ ID No.: 15.

26. **(New)** The NPB of claim 23, comprising a VL domain comprising amino acid residues 134 to 243 of the sequence set forth in SEQ ID No.: 15.

27. **(New)** The NPB of claim 23, comprising a VH domain comprising CDR 1, 2 and 3 regions comprising amino acid residues 16 to 22, 40 to 56, and 89 to 105 respectively of the sequence set forth in SEQ ID No.: 15.

28. **(New)** The NPB of claim 23, comprising a VL domain comprising CDR 1, 2 and 3 regions comprising amino acid residues 157 to 168, 184 to 190, and 222 to 232 respectively of the sequence set forth in SEQ ID No.: 15.

29. **(New)** An isolated NPB, wherein the NPB is an antibody, antibody fragment or bioconjugate that competes for binding to neuropilin-1 with the NPB of claim 24.

30. **(New)** A composition comprising the NPB of claim 23, and a pharmaceutically acceptable carrier

31 **(New)** A method of treating or preventing cancer or metastasis in a patient, the method comprising administering to the patient the NBP according to claim 23 or the composition according to claim 30 in an amount effective to inhibit neuropilin-1 mediated invasion and/or adhesion.